Gilead Sciences, Inc. (NASDAQ:GILD) Position Reduced by Hantz Financial Services Inc.

Hantz Financial Services Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 63,566 shares of the biopharmaceutical company’s stock after selling 7,260 shares during the quarter. Hantz Financial Services Inc.’s holdings in Gilead Sciences were worth $5,872,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter valued at $25,000. Valued Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the second quarter valued at $33,000. Finally, Quarry LP bought a new position in shares of Gilead Sciences in the second quarter valued at $43,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 1.9 %

NASDAQ:GILD opened at $95.59 on Thursday. The firm’s fifty day moving average is $92.00 and its 200-day moving average is $85.44. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market cap of $119.13 billion, a P/E ratio of 1,062.11, a P/E/G ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. The business’s revenue was up 7.0% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Oppenheimer boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Finally, Barclays upped their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.